Genetic engineering of allergens for immunotherapy

Inflammation and Allergy - Drug Targets

Volumn 8, Issue 2, 2009, Pages 104-109

  Bonura, Angela ^a   Colombo, Paolo ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; API M 1 API M 2 API M 3 HYBRID PROTEIN; BET V 1 ALLERGEN; BET V 1 CELL SURFACE PROTEIN FUSION PROTEIN; BET V 1 COR A 1 ALN G 1 CHIMERIC PROTEIN; BIRCH POLLEN EXTRACT; DAU C 1 ALLERGEN; DER F 2 ALLERGEN; HOUSE DUST ALLERGEN; HYBRID PROTEIN; IMMUNOGLOBULIN E; LOL P 5 ALLERGEN; OLE E 1 ALLERGEN; OLE E 1 LIKE ALLERGEN; PAR J 1 ALLERGEN; PAR J 1 PAR J 2 HYBRID PROTEIN; PHL P 12 ALLERGEN; PHL P 2 PHL P 6 HYBRID PROTEIN; PHL P 5 B ALLERGEN; PHL P 6 ALLERGEN; PHL P 7 ALLERGEN; PLACEBO; POLLEN ANTIGEN; POLLEN EXTRACT; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1 ALLERGEN; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIGEN BINDING; ARTICLE; ASTHMA; BIOTECHNOLOGICAL PRODUCTION; BIRCH; CLINICAL TRIAL; CROSS REACTION; DNA SHUFFLING; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SENSITIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EPITOPE MAPPING; GENE REARRANGEMENT; GENETIC ENGINEERING; HAY FEVER; HISTAMINE RELEASE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULAR CLONING; NONHUMAN; OLIGOMERIZATION; PARIETARIA; PERENNIAL RYEGRASS; PHLEUM PRATENSE; PICHIA PASTORIS; POLLEN ALLERGY; PROTEIN BINDING; RHINOCONJUNCTIVITIS; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; VACCINATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; BIOTECHNOLOGY; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; RESPIRATORY HYPERSENSITIVITY;

EID: 70349515095     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152809788462608     Document Type: Article

References (46)

1. Holgate, S.T.; Broide, D. New targets for allergic rhinitis - a disease of civilization. Nat. Rev. Drug Discov., 2003, 2, 902-14.
2. Devereux, G. The increase in the prevalence of asthma and allergy: food for thought. Nat. Rev. Immunol., 2006, 6, 869-74.
3. Radauer, C.; Bublin, M.; Wagner, S.; Mari, A.; Breiteneder, H. Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J. Allergy Clin. Immunol., 2008, 121, 847-52 e7.
4. Chapman, M.D.; Pomes, A.; Breiteneder, H.; Ferreira, F. Nomenclature and structural biology of allergens. J. Allergy Clin. Immunol., 2007, 119, 414-20.
5. Turner, H.; Kinet, J.P. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature, 1999, 402(6760 Suppl), B24-30.
6. Secrist, H.; Chelen, C.J.; Wen, Y.; Marshall, J.D.; Umetsu, D.T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med., 1993, 178, 2123-30.
7. van der Heijden, F.L.; Joost van Neerven, R.J.; van Katwijk, M.; Bos, J.D.; Kapsenberg, M. L. Serum-IgE-facilitated allergen presentation in atopic disease. J. Immunol., 1993, 150, 3643-50.
8. Bousquet, J.; Lockey, R.; Malling, H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol., 1998, 102, 558-62.
9. Mothes, N.; Heinzkill, M.; Drachenberg, K.J.; Sperr, W.R.; Krauth, M.T.; Majlesi, Y.; Semper, H.; Valent, P.; Niederberger, V.; Kraft, D.; Valenta, R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy, 2003, 33, 1198-208.
10. Moverare, R.; Elfman, L.; Vesterinen, E.; Metso, T.; Haahtela, T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy, 2002, 57, 423-30.
11. Focke, M.; Marth, K.; Flicker, S.; Valenta, R. Heterogeneity of commercial timothy grass pollen extracts. Clin. Exp. Allergy, 2008.
12. Moverare, R.; Westritschnig, K.; Svensson, M.; Hayek, B.; Bende, M.; Pauli, G.; Sorva, R.; Haahtela, T.; Valenta, R.; Elfman, L. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int. Arch Allergy Immunol., 2002, 128, 325-35.
13. Kraft, D.; Ferreira, F.; Vrtala, S.; Breiteneder, H.; Ebner, C.; Valenta, R.; Susani, M.; Breitenbach, M.; Scheiner, O. The importance of recombinant allergens for diagnosis and therapy of IgE-mediated allergies. Int. Arch. Allergy Immunol., 1999, 118, 171-6.
14. Valenta, R.; Lidholm, J.; Niederberger, V.; Hayek, B.; Kraft, D.; Gronlund, H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin. Exp. Allergy, 1999, 29, 896-904.
15. Stumvoll, S.; Westritschnig, K.; Lidholm, J.; Spitzauer, S.; Colombo, P.; Duro, G.; Kraft, D.; Geraci, D.; Valenta, R. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J. Allergy Clin. Immunol., 2003, 111, 974-9.
16. Valenta, R.; Twaroch, T.; Swoboda, I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. J. Investig. Allergol. Clin. Immunol., 2007, 17 Suppl 1, 36-40.
17. Valenta, R.; Niederberger, V. Recombinant allergens for immunotherapy. J. Allergy Clin. Immunol., 2007, 119, 826-30.
18. Schramm, G.; Kahlert, H.; Suck, R.; Weber, B.; Stuwe, H.T.; Muller, W.D.; Bufe, A.; Becker, W.M.; Schlaak, M.W.; Jager, L.; Cromwell, O.; Fiebig, H. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol., 1999, 162, 2406-14.
19. Holm, J.; Gajhede, M.; Ferreras, M.; Henriksen, A.; Ipsen, H.; Larsen, J.N.; Lund, L.; Jacobi, H.; Millner, A.; Wurtzen, P.A.; Spangfort, M.D. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J. Immunol., 2004, 173, 5258-67.
20. Swoboda, I.; Bugajska-Schretter, A.; Verdino, P.; Keller, W.; Sperr, W.R.; Valent, P.; Valenta, R.; Spitzauer, S. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J. Immunol., 2002, 168, 4576-84.
21. Marazuela, E.G.; Rodriguez, R.; Barber, D.; Villalba, M.; Batanero, E. Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin. Exp. Allergy, 2007, 37, 251-60.
22. van Hage-Hamsten, M.; Kronqvist, M.; Zetterstrom, O.; Johansson, E.; Niederberger, V.; Vrtala, S.; Gronlund, H.; Gronneberg, R.; Valenta, R. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J. Allergy Clin. Immunol., 1999, 104, 969-77.
23. Vrtala, S.; Akdis, C. A.; Budak, F.; Akdis, M.; Blaser, K.; Kraft, D.; Valenta, R. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol., 2000, 165, 6653-9.
24. Vrtala, S.; Focke, M.; Kopec, J.; Verdino, P.; Hartl, A.; Sperr, W.R.; Fedorov, A.A.; Ball, T.; Almo, S.; Valent, P.; Thalhamer, J.; Keller, W.; Valenta, R. Genetic engineering of the major timothy grass pollen allergen, Ph1 p 6, to reduce allergenic activity and preserve immunogenicity. J. Immunol., 2007, 179, 1730-9.
25. Takai, T.; Yokota, T.; Yasue, M.; Nishiyama, C.; Yuuki, T.; Mori, A.; Okudaira, H.; Okumura, Y. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat. Biotechnol., 1997, 15, 754-8.
26. Bonura, A.; Amoroso, S.; Locorotondo, G.; Di Felice G.; Tinghino, R.; Geraci, D.; Colombo, P. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int. Arch Allergy Immunol., 2001, 126, 32-40.
27. Orlandi, A.; Grasso, F.; Corinti, S.; Marinaro, M.; Bonura, A.; Boirivant, M.; Colombo, P.; Di Felice, G. The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin. Exp. Allergy, 2004, 34, 470-7.
28. Westritschnig, K.; Linhart, B.; Focke-Tejkl, M.; Pavkov, T.; Keller, W.; Ball, T.; Mari, A.; Hartl, A.; Stocklinger, A.; Scheiblhofer, S.; Thalhamer, J.; Ferreira, F.; Vieths, S.; Vogel, L.; Bohm, A.; Valent, P.; Valenta, R. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Ph1 p 12, for the treatment of cross-sensitization to profilin. J. Immunol., 2007, 179, 7624-34.
29. Kahlert, H.; Suck, R.; Weber, B.; Nandy, A.; Wald, M.; Keller, W.; Cromwell, O.; Fiebig, H. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int. Arch Allergy Immunol., 2008, 145, 193-206.
30. Linhart, B.; Valenta, R. Vaccine engineering improved by hybrid technology. Int. Arch Allergy Immunol., 2004, 134, 324-31.
31. Vrtala, S.; Hirtenlehner, K.; Susani, M.; Akdis, M.; Kussebi, F.; Akdis, C.A.; Blaser, K.; Hufnagl, P.; Binder, B.R.; Politou, A.; Pastore, A.; Vangelista, L.; Sperr, W.R.; Semper, H.; Valent, P.; Ebner, C.; Kraft, D.; Valenta, R. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J., 2001, 15, 2045-7.
32. Linhart, B.; Valenta, R. Molecular design of allergy vaccines. Curr. Opin. Immunol., 2005, 17, 646-55.
33. Linhart, B.; Hartl, A.; Jahn-Schmid, B.; Verdino, P.; Keller, W.; Krauth, M.T.; Valent, P.; Horak, F.; Wiedermann, U.; Thalhamer, J.; Ebner, C.; Kraft, D.; Valenta, R. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol., 2005, 115, 1010-6.
34. Bonura, A.; Corinti, S.; Artale, A.; Di Felice, G.; Amoroso, S.; Melis, M.; Geraci, D.; Colombo, P. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int. Arch Allergy Immunol., 2007, 142, 274-84.
35. Karamloo, F.; Schmid-Grendelmeier, P.; Kussebi; F.; Akdis, M.; Salagianni, M.; von Beust, B.R.; Reimers, A.; Zumkehr, J.; Soldatova; L.; Housley-Markovic, Z.; Muller, U.; Kundig, T.; Kemeny, D.M.; Spangfort, M.D.; Blaser, K.; Akdis, C.A. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur. J. Immunol., 2005, 35, 3268-76.
36. Reese, G.; Ballmer-Weber, B.K.; Wangorschc A.; Randow, S.; Vieths, S. Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines. J. Allergy Clin. Immunol., 2007, 119, 944-51.
37. Linhart, B.; Mothes-Luksch, N.; Vrtala, S.; Kneidinger, M.; Valent, P.; Valenta, R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Ph1 p 2 and Ph1 p 6. Biol. Chem., 2008, 389, 925-33.
38. Wallner, M.; Stocklinger, A.; Thalhamer, T.; Bohle, B.; Vogel, L.; Briza, P.; Breiteneder, H.; Vieths, S.; Hartl, A.; Mari, A.; Ebner, C.; Lackner, P.; Hammerl, P.; Thalhamer, J.; Ferreira, F. Allergy multivaccines created by DNA shuffling of tree pollen allergens. J. Allergy Clin. Immunol., 2007, 120, 374-80.
39. Focke, M.; Mahler, V.; Ball, T.; Sperr, W.R.; Majlesi, Y.; Valent, P.; Kraft, D.; Valenta, R. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Ph1 p 1, for allergy vaccination. FASEB J., 2001, 15, 2042-4.
40. Focke, M.; Linhart, B.; Hartl, A.; Wiedermann, U.; Sperr, W.R.; Valent, P.; Thalhamer, J.; Kraft, D.; Valenta, R. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin. Exp. Allergy, 2004, 34, 1525-33.
41. Bohle, B.; Breitwieser, A.; Zwolfer, B.; Jahn-Schmid, B.; Sara, M.; Sleytr, U.B.; Ebner; C. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol., 2004, 172, 6642-8.
42. Gerstmayr, M.; Ilk, N.; Schabussova, I.; Jahn-Schmid, B.; Egelseer, E.M.; Sleytr, U.B.; Ebner, C.; Bohle, B. A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J. Immunol., 2007, 179, 7270-5.
43. Niederberger, V.; Horak, F.; Vrtala, S.; Spitzauer, S.; Krauth, M.T.; Valent, P.; Reisinger, J.; Pelzmann, M.; Hayek, B.; Kronqvist, M.; Gafvelin, G.; Gronlund, H.; Purohit, A.; Suck, R.; Fiebig, H.; Cromwell, O.; Pauli, G.; van Hage-Hamsten, M.; Valenta, R. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 14677-82.
44. Purohit, A.; Niederberger, V.; Kronqvist, M.; Horak, F.; Gronneberg, R.; Suck, R.; Weber, B.; Fiebig, H.; van Hage, M.; Pauli, G.; Valenta, R.; Cromwell, O. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy, 2008.
45. Kettner, J.; Meyer, H.; Narkus, A.; Cromwell, O.; Jost, K. Specific Immunotherapy with recombinant birch allergen rBet v 1-FV is clinicaklly efficacious. Results of a phase III study. XXVI Congress of the European Academy of Allergy and Clinical Immunology 2007.
46. Jutel, M.; Jaeger, L.; Suck, R.; Meyer, H.; Fiebig, H.; Cromwell, O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol., 2005, 116, 608-13.